

Fundamental Biomedical Technologies

Volume 8

Series Editor

Mauro Ferrari, Ph.D. The University of Texas, Houston, TX, USA

More information about this series at <http://www.springer.com/series/7045>

Aleš Prokop • Volkmar Weissig
Editors

Intracellular Delivery III

Market Entry Barriers of Nanomedicines



Springer

Editors

Aleš Prokop
Biomolecular and Chemical Engineering
Vanderbilt University Biomolecular and
Chemical Engineering
Nashville, TN, USA

Volkmar Weissig
Pharmaceutical Sciences
Midwestern University Pharmaceutical
Sciences
GLENDALE, AZ, USA

Intracellular Delivery I: [978-94-007-1247-8](#)
Intracellular Delivery II: ISBN [978-94-017-8895-3](#)

ISSN 1559-7083
Fundamental Biomedical Technologies
ISBN 978-3-319-43523-7 ISBN 978-3-319-43525-1 (eBook)
DOI 10.1007/978-3-319-43525-1

Library of Congress Control Number: 2014939942

© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Contents

Part I Introductory Chapters

- 1 Overview of Present Problems Facing Commercialization of Nanomedicines** 3
Aleš Prokop and Volkmar Weissig
- 2 Precision Drugs and Cell-Specific Drug Delivery** 37
Karel Petrak

Part II EPR Effect and ECM Modification

- 3 Extracellular Matrix Degrading Enzymes for Nanocarrier-Based Anticancer Therapy** 49
Pablo Scodeller
- 4 Nanocarrier-Based Anticancer Therapies with the Focus on Strategies for Targeting the Tumor Microenvironment** 67
Fransisca Leonard and Biana Godin

Part III How to Extend the Circulation Time of Nanovehicles

- 5 A New Approach to Decrease the RES Uptake of Nanodrugs by Pre-administration with Intralipid® Resulting in a Reduction of Toxic Side Effects** 125
Li Liu and Chien Ho

Part IV Differences Between In Vivo Status in Men and Mice

- 6 Authentic Vascular and Stromal Structure in Animal Disease Model for Nanomedicine**..... 149
Hiroshi Nishihara and Mitsunobu R. Kano

Part V Cell-Specific Targeting

7	Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status.....	163
	Roy van der Meel, Laurens J.C. Vehmeijer, Robbert Jan Kok, Gert Storm, and Ethlinn V.B. van Gaal	
8	Anti-angiogenic Therapy by Targeting the Tumor Vasculature with Liposomes.....	201
	Yu Sakurai and Hideyoshi Harashima	
9	Accessing Mitochondrial Targets Using NanoCargos.....	229
	Ru Wen, Afoma C. Umeano, and Shanta Dhar	
10	Redox-Responsive Nano-Delivery Systems for Cancer Therapy.....	255
	Amit Singh, Thanh-Huyen Tran, and Mansoor M. Amiji	

Part VI Improved Imaging

11	Nano-emulsions for Drug Delivery and Biomedical Imaging	273
	Nicolas Anton, François Hallouard, Mohamed F. Attia, and Thierry F. Vandamme	
12	The Tumor Microenvironment in Nanoparticle Delivery and the Role of Imaging to Navigate Roadblocks and Pathways	301
	Dmitri Artemov and Zaver M. Bhujwalla	
13	Microscopic Mass Spectrometry for the Precise Design of Drug Delivery Systems.....	323
	Yasuhiro Matsumura and Masahiro Yasunaga	

Part VII Quantitative PK Treatment, Systems Biology and Drug Discovery

14	Pharmacokinetics and Pharmacodynamics of Nano-Drug Delivery Systems.....	341
	Amit Ranjan Maity and David Stepensky	
15	PBPK Modelling of Intracellular Drug Delivery Through Active and Passive Transport Processes	363
	Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederik Schlender, Michael Block, Thomas Eissing, and Donato Teutonico	
16	Exploiting Nanocarriers for Combination Cancer Therapy.....	375
	Yi Wen Kong, Erik C. Dreaden, Paula T. Hammond, and Michael B. Yaffe	

**Part VIII Market Situation and Commercialization
 of Nanotechnology**

**17 The Commercialization of Medical Nanotechnology
 for Medical Applications..... 405**
 David W. Hobson

Index..... 451

Contributors

Mansoor M. Amiji Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, MA, USA

Nicolas Anton CNRS UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, équipe de Pharmacie Biogalénique, University of Strasbourg, Illkirch Cedex, France

Dmitri Artemov Division of Cancer Imaging Research, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Mohamed F. Attia CNRS UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, équipe de Pharmacie Biogalénique, University of Strasbourg, Illkirch Cedex, France

National Research Center, Cairo, Egypt

Zaver M. Bhujwala Division of Cancer Imaging Research, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Michael Block Complex Systems Modelling, Bayer Technology Service GmbH, Leverkusen, Germany

Shanta Dhar NanoTherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA

Erik C. Dreaden Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

Thomas Eissing Complex Systems Modelling, Bayer Technology Service GmbH, Leverkusen, Germany

Biana Godin Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA

François Hallouard DC2N Inserm U982, Laboratoire de Pharmacie Galénique Biopharmacie, Faculté de Médecine & Pharmacie, Université de Rouen, Rouen, France

Service de Pharmacie, Centre Hospitalier Asselin Hédelin, Yvetot, France

Paula T. Hammond Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, MA, USA

Hideyoshi Harashima Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Chien Ho Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA

David W. Hobson LoneStar PharmTox LLC, Bergheim, TX, USA

Mitsunobu R. Kano Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Robbert Jan Kok Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

Yi Wen Kong Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA

Lars Kuepfer Complex Systems Modelling, Bayer Technology Service GmbH, Leverkusen, Germany

Fransisca Leonard Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA

Li Liu Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA

Amit Ranjan Maity Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Yasuhiro Matsumura Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan

Christoph Niederalt Complex Systems Modelling, Bayer Technology Service GmbH, Leverkusen, Germany

Hiroshi Nishihara Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Translational Research Laboratory, Hokkaido University Hospital, Sapporo, Japan

Karel Petrak NangioTx Inc, Houston, TX, USA

Aleš Prokop Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA

Pharmaceutical Sciences, Midwestern University, Glendale, AZ, USA

Yu Sakurai Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Jan-Frederik Schlender Complex Systems Modelling, Bayer Technology Service GmbH, Leverkusen, Germany

Pablo Scodeller Laboratory of Cancer Biology, Institute of Biomedicine, Center of excellence for translational medicine, University of Tartu, Tartu, Estonia

Amit Singh Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, MA, USA

David Stepensky Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Gert Storm Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands

Donato Teutonico Complex Systems Modelling, Bayer Technology Service GmbH, Leverkusen, Germany

Thanh-Huyen Tran Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, MA, USA

Afoma C. Umeano NanoTherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA

Roy van der Meel Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

Department of Clinical Chemistry & Haematology, University Medical Center Utrecht, Utrecht, The Netherlands

Department of Biochemistry & Molecular Biology, University of British Columbia, Vancouver, BC, Canada

Ethlinn V.B. van Gaal Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

Cristal Therapeutics, Maastricht, The Netherlands

OctoPlus, Leiden, The Netherlands

Thierry F. Vandamme CNRS UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, équipe de Pharmacie Biogalénique, University of Strasbourg, Illkirch Cedex, France

Laurens J.C. Vehmeijer Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

Volkmar Weissig Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA

Pharmaceutical Sciences, Midwestern University, Glendale, AZ, USA

Ru Wen NanoTherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA

Thomas Wendl Complex Systems Modelling, Bayer Technology Service GmbH, Leverkusen, Germany

Michael B. Yaffe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

Divisions of Acute Care Surgery, Trauma, and Critical Care and Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Masahiro Yasunaga Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan

Introduction to Volume III

As a continuation of the previous two volumes, this third volume concentrates on commercial aspects. Unfortunately, obtaining data from the industry has proven to be almost impossible. Thus, we tried collecting manuscripts with emphasis on some preclinical and clinical applications.

Our introductory chapter (Prokop-Weissig) introduces problems associated with the translation of research from the bench to the clinic and subsequently market. This chapter was written by us to serve as an introduction to the entire volume. We failed to get some topics covered, e.g., on patenting as well as on the situation of funding in the USA.

The editors would like to acknowledge the effort of some individuals to peer-review manuscripts submitted by other authors as well as by outside reviewers. These are Fyllos Stylianopoulos, Ales Prokop, Shanta Dhar, Mansoor Amiji, Gerard D'Souza, Biana Godin, Vladimir Torchillin, Hideoyoshi Harashima, Pablo Scodeller, Volkmar Weissig, Nicolas Anton, Lars Kuepfer, Karel Petrak, Sjoerd Hak and

Ales Prokop
Volkmar Weissig